Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Feb
13
2024
Revisiting Government March-In Rights Under Bayh-Dole: The FTC Weighs In Polsinelli PC
Jan
26
2017
FDA's 'Conversation Starter' Paper Suggests Altered Approach for Laboratories Polsinelli PC
Mar
4
2019
Final Rule Regarding the Labeling of Bioengineered Foods Polsinelli PC
Jul
21
2022
District of Columbia Provides Employment Protections for Off-Duty Cannabis Use Polsinelli PC
Oct
12
2022
FDA Issues Final Guidance on Clinical Decision Support Technology with Implications for Software Developers and Providers Polsinelli PC
Oct
21
2020
Drug Manufacturers Unlawfully Target 340B Program Reductions Polsinelli PC
Jan
11
2021
Proposed Regulatory Changes to Safe Harbor Warning Provisions Polsinelli PC
May
9
2019
Florida Now Requires Physicians to Inform Patients About Non-Opioid Alternatives Polsinelli PC
Feb
27
2023
DEA Announces Permanent Flexibilities for the Prescribing of Controlled Substances via Telemedicine Polsinelli PC
Jan
23
2024
Select Highlights from CY 24 Medicare Physician Fee Schedule Final Rule Polsinelli PC
Mar
20
2024
Medicare Changes to Make Drug Coverage More Manageable in 2025 Polsinelli PC
Oct
22
2020
Gaps in Payment for COVID-19 Laboratory Testing Plague Providers and Patients Polsinelli PC
Dec
10
2020
The Fate of the Trump Administration’s Controversial Most Favored Nation Drug Pricing Model Is Unclear Given Mounting Legal Challenges Polsinelli PC
May
2
2017
Nearly Instantaneous Crop Data from Drones Polsinelli PC
May
11
2022
Antitrust Enforcers’ First “Listening Forum” On Merger Reform Highlights Ongoing Concerns in the Food and Agriculture Industry Polsinelli PC
Jun
16
2022
SCOTUS Sides with 340B Hospitals and Denies CMS’s Attempt to Cut Reimbursement for 340B Drugs Polsinelli PC
Feb
13
2023
Missouri Joins States Legalizing Recreational Marijuana – Cutting Through the Haze on Missouri Amendment 3 Polsinelli PC
Sep
27
2019
Retailer Liability for Vaping Products Polsinelli PC
May
1
2023
SCOTUS Appears Poised To Reject Defense-Friendly Safeco Scienter Standard In FCA Cases Polsinelli PC
Mar
21
2016
MedPAC Report Recommends Reduction in Medicare Part B Payments to 340B Hospitals Polsinelli PC
Nov
15
2023
Florida Proposes New Pharmacy Benefit Manager Rules Polsinelli PC
Aug
16
2017
340B Covered Entities Beware: CMS Proposes Drastic Drug Reimbursement Rate Cuts Polsinelli PC
Jan
31
2022
Pharmacy Benefit Managers Licensing and Compliance Developments Polsinelli PC
Feb
25
2022
U.S. Supreme Court Hears Rare 340B Drug Pricing Program Matter with Significant Reimbursement Implications Polsinelli PC
Mar
8
2016
Colorado’s Off-Duty Conduct Statute Does not Protect Employee From Missing an Important Meeting Just Because He was on Pre-Approved Vacation Polsinelli PC
Apr
5
2016
SAMHSA Seeks Comment on Proposed Changes to Address Barriers to Information Sharing Polsinelli PC
Apr
17
2024
What to Know About New York’s New Supplement Law Going into Effect this Month Polsinelli PC
Apr
4
2019
Federal Circuit Addresses Obviousness of Polymorphs in Grunenthal GmbH v. Alkem Labs. Ltd., No. 2017-1153 (Fed. Cir. Mar. 28, 2019) Polsinelli PC
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins